Hier finden Sie den Zugang zur Notfallseite, Kontaktinformationen, Barrierefreiheits-Einstellungen, die Sprachwahl und die Suchfunktion.

Navigation öffnen



DKTK/CCCC LECTURE: "Stratifying Tumours into Functional Subtypes and Identifying Mechanismbased Therapeutic Targets using Multiomics Data"

Zurück zur Übersicht

Sie befinden sich hier:

Veranstaltung ausschließlich für Fachpublikum

Poster DKTK/CCCC Lecture Sadanandam  |  © CCCC
CCM Map | © Charité

Dear colleagues,
It is our great honour and pleasure to announce the DKTK/CCCC Lecture of Dr. Anguraj Sadanandam (Systems and Precision Cancer Medicine, The Institute of Cancer Research, London, UK)
Stratifying Tumours into Functional Subtypes and Identifying Mechanism-based Therapeutic Targets using Multi-omics Data
Date/Time:  Tuesday, June 16th 2015, 4:30 pm   
Venue: Institute of Pathology, Campus Charité Mitte, Lecture Hall Pathology, Virchowweg 15, 10117 Berlin  
Abstract: Dr. Anguraj Sadanandam's Systems and Precision Cancer Medicine Team stratifies different types of tumours and develops appropriate clinical assays by investigating inter- and intra-tumoural heterogeneity at a systems biology level. He applies his multidisciplinary experience both in the wet-lab and computational biology to identify and test personalized therapies for different cancer types.
Tumours vary from patient to patient (inter- and intra-heterogeneous) and exhibit different phenotypic characteristics that result from multiple genetic alterations and/or cellular origin. This heterogeneity contributes to both the variation in course and severity of disease and to the variation in response to current treatment regimes. Recently, we identified tissue-dependent and tissue-independent epithelial and endocrine subtypes in different tumours including pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumours and colorectal cancer using primary tumor samples and multi-omics (molecular profiles) data. These subtypes exhibit differential prognosis, cellular origin/phenotype, metabolism, pathology and responses to current treatment regimens. We are developing Nanostring Technology and immunohistochemistry based assays for these subtypes that could be clinically deployed and useful to classify patients into one of these subtypes. In addition, we are currently redefining the concept of subtyping by introducing a novel method of identifying "functional subtypes" using a single bioinformatics tool that combines omics data with clinical information. This method can be applied to single cell transcriptomics data to understand the intra-tumoural heterogeneity and redefine subtypes in tumours. Overall, we refine and/or develop (molecular/metabolic) biomarkers and assays that will allow for the stratification of patient tumours into subtypes in order to match the most appropriate (personalized) therapy or combination of therapies to confer the greatest benefit to the patient.

Selected Publications
1.   Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, Fletcher-Sananikone E, Lim C, Horwitz GI, Viale A, Pettazzoni P, Sanchez N, Wang H, Protopopov A, Zhang J, Heffernan T,Johnson RL, Chin L, Wang YA, Draetta G, DePinho RA. (2014) Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell, Vol.158(1), pp.185-197.   
2.   Sadanandam, A., Wang, X., de Sousa E Melo, F., Gray, JW., Vermeulen, L., Hanahan, D. & Medema, JP. (2014) Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle, Vol.13 (3), pp.353-357.
3.   Sadanandam A, Gray J, Hanahan D. (2014) Reply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. Nat Med. Vol.20(11), pp.1231-2.
4.   Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D. (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med, Vol.19(5), pp.619-625.

We look very much forward to this lecture and would like to cordially invite you to attend.
Best regards,
Prof. Ulrich Keilholz    Prof. Reinhold Schäfer    Prof. Dr. Bertram Wiedenmann                                     
Acting Director         Deputy Director             Medical Director
CCCC                     CCCC                           of the Charité Center for
                                                              Internal Medicine with
                                                              Gastroenterology and Nephrology

Attendance free



Dr. Anguraj Sadanandam
The Institute of Cancer Research, London, UK


DKTK / Charité Comprehensive Cancer Center (CCCC)


Dienstag, 16.06.2015
16:30 Uhr


Institute of Pathology
Campus Charité Mitte
Lecture Hall Pathology
Virchowweg 15



Please register: DKTK-Berlin(at)

Zurück zur Übersicht